Silvercrest Asset Management Group LLC Buys 323,216 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Silvercrest Asset Management Group LLC increased its position in Cryoport, Inc. (NASDAQ:CYRX) by 77.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 742,914 shares of the company’s stock after acquiring an additional 323,216 shares during the quarter. Silvercrest Asset Management Group LLC owned about 1.50% of Cryoport worth $5,780,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. lifted its stake in Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Cryoport in the fourth quarter worth $51,000. Avanza Fonder AB purchased a new stake in shares of Cryoport in the fourth quarter worth $64,000. Quarry LP bought a new stake in Cryoport during the fourth quarter valued at $69,000. Finally, ProShare Advisors LLC purchased a new position in Cryoport during the fourth quarter worth about $95,000. 92.90% of the stock is currently owned by institutional investors.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 19,830 shares of company stock worth $118,353 in the last ninety days. 10.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have weighed in on CYRX shares. Morgan Stanley lowered their price target on Cryoport from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Roth Mkm reiterated a “buy” rating and set a $15.00 target price on shares of Cryoport in a research report on Tuesday, April 1st. Guggenheim reissued a “buy” rating and issued a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. UBS Group raised their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Cryoport Price Performance

Shares of Cryoport stock opened at $6.68 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 52-week low of $4.58 and a 52-week high of $12.58. The company has a fifty day moving average of $5.95 and a 200-day moving average of $6.86. The stock has a market capitalization of $334.92 million, a price-to-earnings ratio of -1.98 and a beta of 1.92.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. Equities research analysts expect that Cryoport, Inc. will post -0.99 EPS for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.